Morning Overview on MSN
Immunotherapy trial reports 100% remission in a specific rectal cancer group
Every patient in a small clinical trial at Memorial Sloan Kettering Cancer Center saw their rectal cancer vanish after ...
In the overall study population, treatment with dostarlimab-gxly plus chemotherapy reduced the risk of death by 31% vs placebo plus chemotherapy. The Food and Drug Administration (FDA) has accepted ...
Serial Cell-Free DNA Sequencing in ROS1 Fusion–Positive Lung Cancers During Treatment With Entrectinib Participants with PROC who received 1-2 previous lines of therapy were treated with niraparib ...
Morning Overview on MSN
New bowel cancer approach keeps disease at bay for 3 years
Every patient enrolled in a groundbreaking rectal cancer trial has remained disease-free for more than three years after ...
Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with dostarlimab plus ...
GSK PLC's (LSE:GSK, NYSE:GSK) oncology subsidiary TESARO has secured a partial legal victory after a Delaware court dismissed ...
("LIXTE” or the "Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer ...
Use of a neoadjuvant checkpoint inhibitor enabled a high proportion of patients with early-stage mismatch repair-deficient (dMMR) solid tumors to avoid surgery and achieve organ preservation in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results